Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews.
BACKGROUND
The interaction between two non-psychotropic cannabinoids, cannabidiol (CBD) and cannabigerol (CBG), which have been reported to act as a 5-hydroxytryptamine 1A (5-HT(1A)) agonist and antagonist, respectively, was evaluated.


OBJECTIVE
To evaluate the potential of CBG to reverse the anti-nausea, anti-emetic effects of CBD.


METHODS
In experiment 1, rats were pre-treated with CBG (0.0, 1, 5, and 10 mg/kg, ip), 15 min prior to being treated with CBD (experiment 1a: VEH or 5 mg/kg, ip) or 8-OH-DPAT (experiment 1b: VEH or 0.01 mg/kg, ip). Thirty minutes later, all rats received a pairing of 0.1% saccharin solution and LiCl (20 ml/kg of 0.15 M, ip). Seventy-two hours later, the rats received a drug-free taste reactivity test with saccharin to evaluate the effects of the treatments on the establishment of conditioned gaping reactions (a model of nausea). As well, conditioned saccharin avoidance was measured. In experiment 2, Suncus murinus were injected with CBG (5 mg/kg, ip) or VEH 15 min prior to CBD (5 mg/kg) or VEH and 30 min later were injected with LiCl (60 ml/kg of 0.15 M, i.p.), and the number of vomiting episodes were measured.


RESULTS
CBD (5 mg/kg) suppressed conditioned gaping in rats and vomiting in shrews, which were reversed by pre-treatment with all doses of CBG. CBG also prevented the anti-nausea effects of 8-OH-DPAT.


CONCLUSIONS
Interactions between moderate doses of CBG and CBD may oppose one another at the 5-HT(1A) receptor in the regulation of nausea and vomiting.
Department of Psychology, University of Guelph, Guelph, ON, Canada.
Erin M
EM
Rock
Jennifer M
JM
Goodwin
Cheryl L
CL
Limebeer
Aviva
A
Breuer
Roger G
RG
Pertwee
Raphael
R
Mechoulam
Linda A
LA
Parker
D017371:8-Hydroxy-2-(di-n-propylamino)tetralin / Q000494:pharmacology; D000818:Animals; D000932:Antiemetics / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D001362:Avoidance Learning / Q000187:drug effects; D002185:Cannabidiol / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D002186:Cannabinoids / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D002188:Cannabis / Q000737:chemistry*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D012439:Saccharin / Q000008:administration & dosage; D058825:Serotonin 5-HT1 Receptor Agonists / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology; D058829:Serotonin 5-HT1 Receptor Antagonists / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology; D012788:Shrews
D000932:Antiemetics; D002186:Cannabinoids; D058825:Serotonin 5-HT1 Receptor Agonists; D058829:Serotonin 5-HT1 Receptor Antagonists; D002185:Cannabidiol; D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; D012439:Saccharin; C037036:cannabigerol
Pharmacol Biochem Behav. 1989 Jul;33(3):627-31
2531422
J Pharmacol Exp Ther. 2008 Jun;325(3):1007-15
18354058
Physiol Behav. 2006 Jan 30;87(1):66-71
16197970
Psychopharmacology (Berl). 2003 Mar;166(2):156-62
12528012
Physiol Behav. 2009 Apr 20;97(1):121-4
19239915
Neuroreport. 2004 Oct 25;15(15):2381-5
15640760
Psychopharmacology (Berl). 2003 Mar;166(2):120-6
12552358
J Forensic Sci. 2010 Sep;55(5):1209-17
20487147
Stroke. 2005 May;36(5):1077-82
15845890
J Pharmacol Exp Ther. 2006 Sep;318(3):1375-87
16728591
Arch Intern Med. 1980 Nov;140(11):1431-3
6254456
J Nat Prod. 2008 Aug;71(8):1427-30
18681481
Neuroreport. 2002 Apr 16;13(5):567-70
11973447
Pharmacol Biochem Behav. 2001 May-Jun;69(1-2):239-49
11420092
Exp Eye Res. 1984 Sep;39(3):251-9
6499952
Brain Res. 1978 Mar 24;143(2):263-79
630409
Integr Physiol Behav Sci. 2003 Apr-Jun;38(2):133-45
14527182
Psychopharmacology (Berl). 2004 Jul;174(2):254-9
14740147
Gastroenterology. 2001 Oct;121(4):767-74
11606489
Chem Biodivers. 2007 Aug;4(8):1678-92
17712814
Life Sci. 1995;56(23-24):2097-102
7776837
Science. 1970 Jun 5;168(3936):1159-66
4910003
Neurochem Res. 2005 Aug;30(8):1037-43
16258853
BMJ. 2001 Jul 7;323(7303):16-21
11440936
J Dermatol Sci. 2007 Feb;45(2):87-92
17157480
Neuroreport. 1999 Dec 16;10(18):3769-72
10716207
Br J Pharmacol. 2010 Jan;159(1):129-41
20002104
J Pharm Sci. 1982 Dec;71(12):1319-23
7153877
Psychopharmacology (Berl). 2004 Jan;171(2):156-61
13680081
Br J Pharmacol. 2010 Sep;161(2):336-49
20735419
J Clin Pharmacol. 2002 Nov;42(S1):11S-19S
12412831
Behav Neurosci. 1992 Oct;106(5):820-36
1332732
Can J Exp Psychol. 2008 Sep;62(3):198-209
18778149
J Ocul Pharmacol. 1990 Winter;6(4):259-69
1965836
Eur J Pharmacol. 2007 Jun 1;563(1-3):187-96
17362921
Psychopharmacology (Berl). 2008 Feb;196(3):389-95
17992520
N Engl J Med. 1975 Oct 16;293(16):795-7
1099449